CS264222B1 - N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them - Google Patents

N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them Download PDF

Info

Publication number: CS264222B1
Authority: CS; Czechoslovakia
Prior art keywords: formula; compounds; derivatives; bases; evaporated
Prior art date: 1986-07-18

Application number

CS865469A

Other languages

Czech (cs)

English (en)

Other versions

CS546986A1 (en

Inventor

Antonin Rndr Drsc Holy

Ivan Ing Rosenberg

Erik Prof Dr Declercq

Original Assignee

Holy Antonin

Rosenberg Ivan

Erik Prof Dr Declercq

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-07-18

Filing date

1986-07-18

Publication date

1989-06-13

1986-07-18 Application filed by Holy Antonin, Rosenberg Ivan, Erik Prof Dr Declercq filed Critical Holy Antonin

1986-07-18 Priority to CS865469A priority Critical patent/CS264222B1/cs

1987-07-16 Priority to NZ221100A priority patent/NZ221100A/xx

1987-07-17 Priority to DE1997175085 priority patent/DE19775085I2/de

1987-07-17 Priority to ZA875283A priority patent/ZA875283B/xx

1987-07-17 Priority to IL83235A priority patent/IL83235A/xx

1987-07-17 Priority to CA000542404A priority patent/CA1340856C/fr

1987-07-17 Priority to DE8787110399T priority patent/DE3765864D1/de

1987-07-17 Priority to AT87110399T priority patent/ATE57932T1/de

1987-07-17 Priority to IE194487A priority patent/IE60117B1/en

1987-07-17 Priority to ES198787110399T priority patent/ES2036194T3/es

1987-07-17 Priority to FI873165A priority patent/FI86856C/fi

1987-07-17 Priority to EP87110399A priority patent/EP0253412B1/fr

1987-07-17 Priority to DK373487A priority patent/DK170646B1/da

1987-07-17 Priority to AU75759/87A priority patent/AU600002B2/en

1987-07-17 Priority to US07/074,900 priority patent/US5142051A/en

1987-07-18 Priority to JP62179877A priority patent/JPH0822866B2/ja

1987-07-18 Priority to KR87007844A priority patent/KR950004179B1/ko

1987-07-19 Priority to EG42/87A priority patent/EG18273A/xx

1987-07-20 Priority to PT85354A priority patent/PT85354B/pt

1988-08-16 Publication of CS546986A1 publication Critical patent/CS546986A1/cs

1989-06-13 Publication of CS264222B1 publication Critical patent/CS264222B1/cs

1990-11-19 Priority to GR90400937T priority patent/GR3002534T3/el

1994-10-11 Priority to US08/320,591 priority patent/US5641763A/en

1995-03-28 Priority to US08/412,398 priority patent/US5869467A/en

1997-10-01 Priority to NL970036C priority patent/NL970036I2/nl

1997-10-21 Priority to LU90155C priority patent/LU90155I2/fr

Links

KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title claims abstract description 12
238000000034 method Methods 0.000 title abstract description 6
239000002585 base Substances 0.000 claims description 24
-1 pyrimidin-1-yl Chemical group 0.000 claims description 15
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 5
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
229910052783 alkali metal Inorganic materials 0.000 claims description 3
150000001340 alkali metals Chemical class 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
125000000848 adenin-9-yl group Chemical group [H]N([H])C1=C2N=C([H])N(*)C2=NC([H])=N1 0.000 claims description 2
229910021529 ammonia Inorganic materials 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000004543 purin-7-yl group Chemical group N1=CN=C2N=CN(C2=C1)* 0.000 claims description 2
125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 56
125000000623 heterocyclic group Chemical group 0.000 abstract description 20
230000000840 anti-viral effect Effects 0.000 abstract description 13
238000006243 chemical reaction Methods 0.000 abstract description 13
238000002360 preparation method Methods 0.000 abstract description 11
150000003230 pyrimidines Chemical class 0.000 abstract description 2
230000001747 exhibiting effect Effects 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000243 solution Substances 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
239000000203 mixture Substances 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
241000700605 Viruses Species 0.000 description 13
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 8
159000000000 sodium salts Chemical class 0.000 description 8
239000002253 acid Substances 0.000 description 7
230000009471 action Effects 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical class O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 7
MTVWFVDWRVYDOR-UHFFFAOYSA-N 3,4-Dihydroxyphenylglycol Chemical compound OCC(O)C1=CC=C(O)C(O)=C1 MTVWFVDWRVYDOR-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
FRPXSOOHWNMLPH-LURJTMIESA-N [(2s)-1-(6-aminopurin-9-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid Chemical compound NC1=NC=NC2=C1N=CN2C[C@@H](CO)OCP(O)(O)=O FRPXSOOHWNMLPH-LURJTMIESA-N 0.000 description 6
239000000872 buffer Substances 0.000 description 5
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000000694 effects Effects 0.000 description 5
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 5
229920001467 poly(styrenesulfonates) Polymers 0.000 description 5
239000011734 sodium Substances 0.000 description 5
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
229930024421 Adenine Natural products 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
229960000643 adenine Drugs 0.000 description 4
239000003729 cation exchange resin Substances 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 4
235000015097 nutrients Nutrition 0.000 description 4
239000000047 product Substances 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
230000001790 virustatic effect Effects 0.000 description 4
HOOWCUZPEFNHDT-UHFFFAOYSA-N DHPG Natural products OC(=O)C(N)C1=CC(O)=CC(O)=C1 HOOWCUZPEFNHDT-UHFFFAOYSA-N 0.000 description 3
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
229920005654 Sephadex Polymers 0.000 description 3
239000012507 Sephadex™ Substances 0.000 description 3
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
125000002015 acyclic group Chemical group 0.000 description 3
238000009835 boiling Methods 0.000 description 3
230000000120 cytopathologic effect Effects 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
239000002777 nucleoside Substances 0.000 description 3
229940127073 nucleoside analogue Drugs 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
238000003756 stirring Methods 0.000 description 3
241001529453 unidentified herpesvirus Species 0.000 description 3
229940107931 zovirax Drugs 0.000 description 3
IUUBODMNDCMSEU-UHFFFAOYSA-N 3-[6-amino-3-(3-hydroxypropyl)-2,4,5,9-tetrahydropurin-2-yl]propan-1-ol Chemical compound NC1=NC(CCCO)N(CCCO)C2N=CNC12 IUUBODMNDCMSEU-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
241000450599 DNA viruses Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
SUPKOOSCJHTBAH-UHFFFAOYSA-N adefovir Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
FZXSSJIKXCFPDP-UHFFFAOYSA-N chloro(dichlorophosphoryl)methane Chemical compound ClCP(Cl)(Cl)=O FZXSSJIKXCFPDP-UHFFFAOYSA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
238000010828 elution Methods 0.000 description 2
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000010626 work up procedure Methods 0.000 description 2
229940075420 xanthine Drugs 0.000 description 2
GSLQFBVNOFBPRJ-YFKPBYRVSA-N (2s)-3-(6-aminopurin-9-yl)propane-1,2-diol Chemical compound NC1=NC=NC2=C1N=CN2C[C@H](O)CO GSLQFBVNOFBPRJ-YFKPBYRVSA-N 0.000 description 1
LVOASXNJWPROPP-UHFFFAOYSA-N (4-methylphenyl)sulfonyloxymethylphosphonic acid Chemical compound CC1=CC=C(S(=O)(=O)OCP(O)(O)=O)C=C1 LVOASXNJWPROPP-UHFFFAOYSA-N 0.000 description 1
JCOLUXJISZCBEN-UHFFFAOYSA-N 1-bromo-2-(diethoxyphosphorylmethoxy)ethane Chemical compound CCOP(=O)(OCC)COCCBr JCOLUXJISZCBEN-UHFFFAOYSA-N 0.000 description 1
WJSVJNDMOQTICG-UHFFFAOYSA-N 2-amino-1-[(2-methyl-4-methylidene-5-oxooxolan-2-yl)methyl]-7h-purin-6-one Chemical compound NC1=NC=2N=CNC=2C(=O)N1CC1(C)CC(=C)C(=O)O1 WJSVJNDMOQTICG-UHFFFAOYSA-N 0.000 description 1
DVQJDXCYEPGOCF-UHFFFAOYSA-N 2-amino-9-(4-hydroxybutyl)-3h-purin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N(CCCCO)C=N2 DVQJDXCYEPGOCF-UHFFFAOYSA-N 0.000 description 1
VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 1
UHOFECKRSHSYNE-UHFFFAOYSA-N 3-(6-aminopurin-9-yl)-2-hydroxypropanoic acid Chemical compound NC1=NC=NC2=C1N=CN2CC(O)C(O)=O UHOFECKRSHSYNE-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
VQIIGZBDLZQJKL-UHFFFAOYSA-N 5-benzyl-1-(1,3-dihydroxypropan-2-yloxymethyl)pyrimidine-2,4-dione Chemical compound O=C1NC(=O)N(COC(CO)CO)C=C1CC1=CC=CC=C1 VQIIGZBDLZQJKL-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
101150018711 AASS gene Proteins 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
102000009097 Phosphorylases Human genes 0.000 description 1
108010073135 Phosphorylases Proteins 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910001854 alkali hydroxide Inorganic materials 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
229910000062 azane Inorganic materials 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
UCKORWKZRPKRQE-UHFFFAOYSA-N bromo(triethyl)silane Chemical compound CC[Si](Br)(CC)CC UCKORWKZRPKRQE-UHFFFAOYSA-N 0.000 description 1
IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000001369 canonical nucleoside group Chemical group 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000007806 chemical reaction intermediate Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000009615 deamination Effects 0.000 description 1
238000006481 deamination reaction Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
238000006477 desulfuration reaction Methods 0.000 description 1
230000023556 desulfurization Effects 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
229960002819 diprophylline Drugs 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
150000002641 lithium Chemical class 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000000155 melt Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
238000000844 transformation Methods 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
125000000845 uracil-1-yl group Chemical group [*]N1C(=O)N([H])C(=O)C([H])=C1[H] 0.000 description 1
229960003636 vidarabine Drugs 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CS865469A 1986-07-18 1986-07-18 N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them CS264222B1 (en)

Priority Applications (24)

Application Number	Priority Date	Filing Date	Title
CS865469A CS264222B1 (en)	1986-07-18	1986-07-18	N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
NZ221100A NZ221100A (en)	1986-07-18	1987-07-16	N-phosphonylmethoxyalkyl pyrimidines and purines and pharmaceutical compositions thereof
EP87110399A EP0253412B1 (fr)	1986-07-18	1987-07-17	Dérivés N-phosphonométhoxyalkyliques de bases de pyrimidine et de purine, leur procédé de préparation, compositions pharmaceutiques les contenant avec activité antivirale
AU75759/87A AU600002B2 (en)	1986-07-18	1987-07-17	N-phosphonylmethoxyalkyl pyrimidines and purines and therapeutic application thereof
IL83235A IL83235A (en)	1986-07-18	1987-07-17	N-phosphonylmethoxyalkyl pyrimidines and purines and therapeutic application thereof
CA000542404A CA1340856C (fr)	1986-07-18	1987-07-17	Purines etpyrimidines n-phosphonylmethoxyalkyliques; leur emploi a des fins therapeutiques
DE8787110399T DE3765864D1 (de)	1986-07-18	1987-07-17	N-phosphonylmethoxyalkyl-derivate von pyrimidin- und purinbasen, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen mit antiviraler wirkung, die sie enthalten.
AT87110399T ATE57932T1 (de)	1986-07-18	1987-07-17	N-phosphonylmethoxyalkyl-derivate von pyrimidin- und purinbasen, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen mit antiviraler wirkung, die sie enthalten.
IE194487A IE60117B1 (en)	1986-07-18	1987-07-17	N-phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases, methods for their preparation and pharmaceutical compositions therefrom with antiviral activity
ES198787110399T ES2036194T3 (es)	1986-07-18	1987-07-17	Derivados n-fosfonilmetoxialquilicos de bases de pirimidina y purina, metodos para su preparacion y composiciones farmaceuticas basadas en ellos, con actividad antivirica.
FI873165A FI86856C (fi)	1986-07-18	1987-07-17	Foerfarande foer framstaellning av n-fosfonylmetoxialkylpyrimidiner och -puriner
DE1997175085 DE19775085I2 (de)	1986-07-18	1987-07-17	N-Phosphonylmethoxyalkyl-Derivate von Pyrimidin- und Purinbasen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen mit antiviraler Wirkung, die sie enthalten.
DK373487A DK170646B1 (da)	1986-07-18	1987-07-17	N-fosfonylmetoxyalkylderivater af pyrimidinbaser og purinbaser, fremgangsmåder til fremstilling heraf, samt lægemiddelpræparat med antiviral virkning indeholdende et sådant derivat
ZA875283A ZA875283B (en)	1986-07-18	1987-07-17	N-phosphonylmethoxyalkyl pyrimidines and purines and therapeutic application thereof
US07/074,900 US5142051A (en)	1986-07-18	1987-07-17	N-phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases and a therapeutical composition therefrom with antiviral activity
JP62179877A JPH0822866B2 (ja)	1986-07-18	1987-07-18	プリンおよびピリミジン塩基のｎ−ホスホニルメトキシアルキル誘導体
KR87007844A KR950004179B1 (en)	1986-07-18	1987-07-18	N-phosphonylmethoxyalkye derivatives of pyrimidine and purine bases and a therapeutical composition therefrom with antiviral activity
EG42/87A EG18273A (en)	1986-07-18	1987-07-19	N-phosphonylmethoxyalkyl pyrimidines and purines and therapeutic application thereof
PT85354A PT85354B (pt)	1986-07-18	1987-07-20	Processo de preparacao de derivados n-fosfonilmetoxialquilo de bases pirimidina e purina e de composicoes farmaceuticas que os contem
GR90400937T GR3002534T3 (en)	1986-07-18	1990-11-19	N-phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases, methods for their preparation and pharmaceutical compositions therefrom with antiviral activity
US08/320,591 US5641763A (en)	1986-07-18	1994-10-11	N-phosphonylmethoxyalkyl derivatives of pyrimdine and purine bases and a therapeutical composition therefrom with antiviral activity
US08/412,398 US5869467A (en)	1986-07-18	1995-03-28	9-(2-phosphonylmethoxyethyl) guanine
NL970036C NL970036I2 (nl)	1986-07-18	1997-10-01	N-fosfonylmethoxyalkylderivaten van pyrimidine en purinebasen, werkwijze voor de bereiding hiervan en farmaceutische samenstellingen hiervan met een antivirale activiteit.
LU90155C LU90155I2 (fr)	1986-07-18	1997-10-21	Vistide - cidofovir 75 mg/ml

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CS865469A CS264222B1 (en)	1986-07-18	1986-07-18	N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them

Publications (2)

Publication Number	Publication Date
CS546986A1 CS546986A1 (en)	1988-08-16
CS264222B1 true CS264222B1 (en)	1989-06-13

Family

ID=5399635

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS865469A CS264222B1 (en)	1986-07-18	1986-07-18	N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them

Country Status (21)

Country	Link
US (3)	US5142051A (fr)
EP (1)	EP0253412B1 (fr)
JP (1)	JPH0822866B2 (fr)
KR (1)	KR950004179B1 (fr)
AT (1)	ATE57932T1 (fr)
AU (1)	AU600002B2 (fr)
CA (1)	CA1340856C (fr)
CS (1)	CS264222B1 (fr)
DE (2)	DE3765864D1 (fr)
DK (1)	DK170646B1 (fr)
EG (1)	EG18273A (fr)
ES (1)	ES2036194T3 (fr)
FI (1)	FI86856C (fr)
GR (1)	GR3002534T3 (fr)
IE (1)	IE60117B1 (fr)
IL (1)	IL83235A (fr)
LU (1)	LU90155I2 (fr)
NL (1)	NL970036I2 (fr)
NZ (1)	NZ221100A (fr)
PT (1)	PT85354B (fr)
ZA (1)	ZA875283B (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CS264222B1 (en) *	1986-07-18	1989-06-13	Holy Antonin	N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) *	1986-11-18	1997-07-22	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
NZ222553A (en) *	1986-11-18	1991-07-26	Bristol Myers Co	Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions
JPH0217199A (ja) *	1988-07-05	1990-01-22	Japan Tobacco Inc	２’−デオキシ−β−アデノシンの製造方法
US5688778A (en) *	1989-05-15	1997-11-18	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Nucleoside analogs
US5302585A (en) *	1990-04-20	1994-04-12	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
PT97407B (pt) *	1990-04-20	1998-08-31	Rega Stichting	Processo para a preparacao de (r)-9-{2-(fosfono-metoxi)-propil}-guanina
CZ285420B6 (cs) *	1990-04-24	1999-08-11	Ústav Organické Chemie A Biochemie Avčr	N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití
CS387190A3 (en) *	1990-08-06	1992-03-18	Ustav Organicke Chemie A Bioch	(2r)-2-/di(2-propyl)phosphonylmethoxy/-3-p-toluenesulfonyloxy -1- trimethylacetoxypropane and process for preparing thereof
JP3116079B2 (ja) *	1990-08-10	2000-12-11	インスティチュートオブオーガニックケミストリアンドバイオケミストリアカデミーオブサイエンスオブザチェコリパブリック	ヌクレオチドの新規な製法
EP0481214B1 (fr) *	1990-09-14	1998-06-24	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Pro-médicaments dérivés de phosphonates
US5208221A (en) *	1990-11-29	1993-05-04	Bristol-Myers Squibb Company	Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
HU225970B1 (en) *	1991-10-11	2008-01-28	Acad Of Science Czech Republic	Antiviral acyclic phosphonomethoxyalkyl-substituted alkenyl purine and pyrimidine derivatives, and pharmaceutical preparations containing them
US6057305A (en)	1992-08-05	2000-05-02	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Antiretroviral enantiomeric nucleotide analogs
US5817647A (en) *	1993-04-01	1998-10-06	Merrell Pharmaceuticals Inc.	Unsaturated acetylene phosphonate derivatives of purines
US5514798A (en) *	1993-06-02	1996-05-07	Gilead Sciences, Inc.	Method and cyclic carbonates for nucleotide analogues
US5798340A (en)	1993-09-17	1998-08-25	Gilead Sciences, Inc.	Nucleotide analogs
US5656745A (en) *	1993-09-17	1997-08-12	Gilead Sciences, Inc.	Nucleotide analogs
US5502177A (en)	1993-09-17	1996-03-26	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
CA2171868A1 (fr) *	1993-09-17	1995-03-23	Petr Alexander	Methode pour le dosage de composes therapeutiques
NZ283658A (en) *	1994-04-04	1999-09-29	William R Freeman	Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
US5468752A (en) *	1994-04-04	1995-11-21	Freeman; William R.	Treatment of conditions of abnormally increased intraocular pressure by administration of HPMPC and related phosphonylmethoxyalkylcytosines
US5977061A (en) *	1995-04-21	1999-11-02	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	N6 - substituted nucleotide analagues and their use
US5717095A (en) *	1995-12-29	1998-02-10	Gilead Sciences, Inc.	Nucleotide analogs
US6093816A (en)	1996-06-27	2000-07-25	Isis Pharmaceuticals, Inc.	Cationic lipids
US5922695A (en) *	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
CN1900091A (zh) *	1997-07-25	2007-01-24	吉尔利德科学股份有限公司	核苷酸类似物组合物
DE69939604D1 (de) *	1998-11-02	2008-10-30	Gilead Sciences Inc	Kombinationstherapie zur Behandlung von Hepatitis B Infektionen
US6407077B1 (en)	1998-11-05	2002-06-18	Emory University	β-L nucleosides for the treatment of HIV infection
US7205404B1 (en)	1999-03-05	2007-04-17	Metabasis Therapeutics, Inc.	Phosphorus-containing prodrugs
IL150594A0 (en) *	2000-01-07	2003-02-12	Ustav Ex Botan Adademie Ved Ce	Purine derivatives, process for their preparation and use
AUPQ806700A0 (en) *	2000-06-08	2000-07-06	Commonwealth Scientific And Industrial Research Organisation	Antiviral agents
US20020119443A1 (en)	2000-07-21	2002-08-29	Gilead Sciences, Inc.	Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
CN102942563A (zh)	2001-03-01	2013-02-27	基利得科学公司	顺-ftc的多晶型物及其它晶型
EP1406911B1 (fr)	2001-06-29	2016-01-06	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Dérivés de 6-[2-(phosphonomethoxy)alkoxy] pyrimidine et leur activité antivirale
US7247621B2 (en) *	2002-04-30	2007-07-24	Valeant Research & Development	Antiviral phosphonate compounds and methods therefor
EP2223927B1 (fr)	2002-05-13	2014-10-15	Metabasis Therapeutics, Inc.	Sels d' un Pro-médicament de PMEA à base d'acide phosphonique
WO2003095665A2 (fr)	2002-05-13	2003-11-20	Metabasis Therapeutics, Inc.	Procede d'elaboration de promedicaments cycliques de pmea et de pmpa
DK1583542T3 (da)	2003-01-14	2008-09-22	Gilead Sciences Inc	Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
NZ543864A (en)	2003-06-16	2009-10-30	Leuven K U Res & Dev	Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
US20050080053A1 (en) *	2003-08-29	2005-04-14	Biocryst Pharmaceuticals, Inc.	Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005051318A2 (fr) *	2003-11-24	2005-06-09	Viropharma Incorporated	Composes, compositions et procedes pour le traitement et la prophylaxie d'infections de l'hepatite c virale et de maladies associees
WO2005090370A1 (fr) *	2004-02-05	2005-09-29	The Regents Of The University Of California	Agents pharmacologiquement actifs contenant des phosphonates esterifies, et leurs procedes d'utilisation
US7754718B2 (en)	2004-05-05	2010-07-13	Yale University	Antiviral helioxanthin analogs
CA2565966A1 (fr) *	2004-06-08	2005-12-29	Metabasis Therapeutics, Inc.	Synthese d'esters cycliques induite par l'acide de lewis
ES2401285T3 (es)	2004-12-16	2013-04-18	The Regents Of The University Of California	Fármacos con el pulmón como diana
US20090156545A1 (en) *	2005-04-01	2009-06-18	Hostetler Karl Y	Substituted Phosphate Esters of Nucleoside Phosphonates
US8642577B2 (en) *	2005-04-08	2014-02-04	Chimerix, Inc.	Compounds, compositions and methods for the treatment of poxvirus infections
EP2842559A3 (fr) *	2005-04-08	2015-03-18	Chimerix, Inc.	Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN100526315C (zh)	2005-06-16	2009-08-12	浙江医药股份有限公司新昌制药厂	N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途
MX2008001166A (es) *	2005-07-25	2008-03-18	Intermune Inc	Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
AU2006301966A1 (en)	2005-10-11	2007-04-19	Array Biopharma, Inc.	Compounds and methods for inhibiting hepatitis C viral replication
US8076303B2 (en)	2005-12-13	2011-12-13	Spring Bank Pharmaceuticals, Inc.	Nucleotide and oligonucleotide prodrugs
FR2908133B1 (fr) *	2006-11-08	2012-12-14	Centre Nat Rech Scient	Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
GB0709408D0 (en) *	2007-05-16	2007-06-27	Katholleke Universiteit Leuven	Anti-col herpes virus compounds
US20090181931A1 (en) *	2008-01-16	2009-07-16	Oncolys Biopharma, Inc.	Antiviral activity of cidofovir against oncolytic viruses
ES2572631T3 (es)	2008-01-25	2016-06-01	Chimerix, Inc.	Métodos de tratamiento de infecciones virales
TWI444384B (zh)	2008-02-20	2014-07-11	Gilead Sciences Inc	核苷酸類似物及其在治療惡性腫瘤上的用途
WO2009120358A1 (fr) *	2008-03-27	2009-10-01	Nektar Therapeutics	Conjugués oligomère-base azotée
EA201071034A1 (ru) *	2008-04-15	2011-06-30	Интермьюн, Инк.	Новые макроциклические ингибиторы репликаций вируса гепатита с
EP2358736A1 (fr) *	2008-10-15	2011-08-24	Intermune, Inc.	Peptides antiviraux therapeutiques
WO2011011519A1 (fr)	2009-07-21	2011-01-27	Chimerix, Inc.	Composés, compositions et procédés pour traiter des troubles oculaires
CA2770282A1 (fr)	2009-08-03	2011-02-10	Chimerix, Inc.	Composition et methodes de traitement des infections virales et des tumeurs d'origine virale
TW201116540A (en) *	2009-10-01	2011-05-16	Intermune Inc	Therapeutic antiviral peptides
US9006218B2 (en)	2010-02-12	2015-04-14	Chimerix Inc.	Nucleoside phosphonate salts
EP2371369A1 (fr)	2010-04-01	2011-10-05	Institut Gustave Roussy (IGR)	Inhibiteur EGFR et agent antiviral pour une utilisation simultanée, séparée ou séquentielle pour le traitement, la prévention et/ou la palliation du cancer
CA2797601A1 (fr)	2010-04-26	2011-11-10	Chimerix, Inc.	Methodes de traitement d'infections retrovirales et regimes posologiques associes
WO2012079035A1 (fr)	2010-12-10	2012-06-14	Sigmapharm Laboratories, Llc	Compositions très stables d'analogues nucléotidiques actifs par voie orale ou de promédicaments sous forme d'analogues nucléotidiques actifs par voie orale
EP2667874A4 (fr) *	2011-01-27	2014-07-30	Univ Princeton	Inhibiteurs de kinase mtor en tant qu'agents antiviraux
WO2012138954A1 (fr)	2011-04-07	2012-10-11	Johnson Matthey Public Limited Company	Formes de cidofovir
EP3578563B1 (fr)	2011-12-22	2021-04-14	Geron Corporation	Analogues de guanine en tant que substrats de télomérase et d'agents affecteurs de longueur de télomère
EP2846788A1 (fr)	2012-05-11	2015-03-18	Akron Molecules AG	Utilisation de composés pour le traitement de la douleur
EP2912047B1 (fr)	2012-10-29	2016-08-24	Cipla Limited	Analogues de phosphonate antiviraux et leur procédé de préparation
SG10201800188SA (en)	2013-03-15	2018-02-27	Univ California	Acyclic nucleoside phosphonate diesters
AU2015217221A1 (en)	2014-02-13	2016-08-11	Ligand Pharmaceuticals, Inc.	Prodrug compounds and their uses
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
CN111808136B (zh)	2014-09-15	2024-06-11	加利福尼亚大学董事会	核苷酸类似物
EP3350191B9 (fr)	2015-09-15	2021-12-22	The Regents of the University of California	Analogues nucléotidiques
AU2017231824B2 (en) *	2016-03-09	2021-07-01	Alios Biopharma, Inc.	Acyclic antivirals
CA3087932A1 (fr)	2018-01-09	2019-07-18	Ligand Pharmaceuticals, Inc.	Composes acetal et leurs utilisations therapeutiques
US12404332B2 (en)	2020-03-13	2025-09-02	Research Development Foundation	Methods for diagnosing and treating cancers
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
KR20250052378A (ko)	2022-07-21	2025-04-18	안티바 바이오사이언시즈, 인크.	Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4287188A (en) *	1977-02-24	1981-09-01	Burroughs Wellcome Co.	Purine derivatives
AU521577B2 (en) *	1977-02-24	1982-04-22	Wellcome Foundation Limited, The	9-hydroxyethoxymethyl guanine phosphates
DE2909709A1 (de) *	1979-03-12	1980-09-25	Kailash Kumar Dr Gauri	Verfahren zur herstellung von nucleotidderivaten, neue nucleotidderivate und daraus hergestellte arzneimittel
DK448983A (da) *	1982-09-30	1984-03-31	Syntex Inc	1-monophosphatestere, 1,3-bisphosphatestere og cykliske phosphatestere af 9-(1,3-dihydroxy-2-propoxymethyl)guanin som antivirale midler
CS233665B1 (en) *	1983-01-06	1985-03-14	Antonin Holy	Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
US5047533A (en) *	1983-05-24	1991-09-10	Sri International	Acyclic purine phosphonate nucleotide analogs
IL72173A0 (en) *	1983-06-24	1984-10-31	Merck & Co Inc	Guanine derivatives,their preparation and pharmaceutical compositions containing them
US4670424A (en) *	1983-09-19	1987-06-02	Merck & Co., Inc.	Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides
US4590269A (en) *	1984-03-29	1986-05-20	Syntex (U.S.A.) Inc.	Process for preparing the cyclic phosphate ester of substituted 9-(1,3-dihydroxy-2-propoxymethyl)purines
US4579849A (en) *	1984-04-06	1986-04-01	Merck & Co., Inc.	N-alkylguanine acyclonucleosides as antiviral agents
CS263951B1 (en) *	1985-04-25	1989-05-12	Antonin Holy	9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) *	1985-04-25	1989-05-12	Holy Antonin	Remedy with antiviral effect
CS264222B1 (en) *	1986-07-18	1989-06-13	Holy Antonin	N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
NZ222553A (en) *	1986-11-18	1991-07-26	Bristol Myers Co	Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions
CA1330794C (fr) *	1987-03-27	1994-07-19	Phillip Frost	Composes antiviraux, formes et methodes pharmaceutiques

1986
- 1986-07-18 CS CS865469A patent/CS264222B1/cs not_active IP Right Cessation
1987
- 1987-07-16 NZ NZ221100A patent/NZ221100A/xx unknown
- 1987-07-17 DE DE8787110399T patent/DE3765864D1/de not_active Expired - Lifetime
- 1987-07-17 ES ES198787110399T patent/ES2036194T3/es not_active Expired - Lifetime
- 1987-07-17 IE IE194487A patent/IE60117B1/en not_active IP Right Cessation
- 1987-07-17 FI FI873165A patent/FI86856C/fi not_active IP Right Cessation
- 1987-07-17 US US07/074,900 patent/US5142051A/en not_active Expired - Lifetime
- 1987-07-17 AT AT87110399T patent/ATE57932T1/de active
- 1987-07-17 DE DE1997175085 patent/DE19775085I2/de active Active
- 1987-07-17 EP EP87110399A patent/EP0253412B1/fr not_active Expired - Lifetime
- 1987-07-17 IL IL83235A patent/IL83235A/xx not_active IP Right Cessation
- 1987-07-17 DK DK373487A patent/DK170646B1/da not_active IP Right Cessation
- 1987-07-17 ZA ZA875283A patent/ZA875283B/xx unknown
- 1987-07-17 CA CA000542404A patent/CA1340856C/fr not_active Expired - Lifetime
- 1987-07-17 AU AU75759/87A patent/AU600002B2/en not_active Expired
- 1987-07-18 KR KR87007844A patent/KR950004179B1/ko not_active Expired - Lifetime
- 1987-07-18 JP JP62179877A patent/JPH0822866B2/ja not_active Expired - Lifetime
- 1987-07-19 EG EG42/87A patent/EG18273A/xx active
- 1987-07-20 PT PT85354A patent/PT85354B/pt unknown
1990
- 1990-11-19 GR GR90400937T patent/GR3002534T3/el unknown
1994
- 1994-10-11 US US08/320,591 patent/US5641763A/en not_active Expired - Lifetime
1995
- 1995-03-28 US US08/412,398 patent/US5869467A/en not_active Expired - Lifetime
1997
- 1997-10-01 NL NL970036C patent/NL970036I2/nl unknown
- 1997-10-21 LU LU90155C patent/LU90155I2/fr unknown

Also Published As

Publication number	Publication date
IL83235A0 (en)	1987-12-31
FI873165L (fi)	1988-01-19
KR950004179B1 (en)	1995-04-27
EP0253412A2 (fr)	1988-01-20
NZ221100A (en)	1991-09-25
AU7575987A (en)	1988-01-21
EP0253412A3 (en)	1989-04-26
KR880001688A (ko)	1988-04-26
ATE57932T1 (de)	1990-11-15
ES2036194T3 (es)	1993-05-16
JPH0822866B2 (ja)	1996-03-06
IE60117B1 (en)	1994-06-01
DK170646B1 (da)	1995-11-20
CS546986A1 (en)	1988-08-16
IE871944L (en)	1988-01-18
PT85354B (pt)	1990-04-30
DK373487A (da)	1988-01-19
AU600002B2 (en)	1990-08-02
JPS6345289A (ja)	1988-02-26
US5641763A (en)	1997-06-24
DK373487D0 (da)	1987-07-17
DE3765864D1 (de)	1990-12-06
NL970036I1 (nl)	1997-12-01
US5869467A (en)	1999-02-09
ZA875283B (en)	1988-03-30
LU90155I2 (fr)	1997-12-22
EG18273A (en)	1992-12-30
GR3002534T3 (en)	1993-01-25
FI873165A0 (fi)	1987-07-17
FI86856B (fi)	1992-07-15
CA1340856C (fr)	1999-12-21
DE19775085I2 (de)	2004-01-15
NL970036I2 (nl)	1998-03-02
US5142051A (en)	1992-08-25
EP0253412B1 (fr)	1990-10-31
PT85354A (en)	1987-08-01
FI86856C (fi)	1992-10-26
IL83235A (en)	1992-11-15

Legal Events

Date	Code	Title	Description
2000-06-30	IF00	In force as of 2000-06-30 in czech republic
2001-09-12	MK4A	Patent expired	Effective date: 20010718

Publication	Publication Date	Title
CS264222B1 (en)	1989-06-13	N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
CA2141589C (fr)	2007-04-17	Analogues de nucleotides enantiomeres antiretroviraux
EP0821690B1 (fr)	2012-06-13	Analogues de nucléotides pour le traitement des infections virales
US7790735B2 (en)	2010-09-07	Methanocarba cycloalkyl nucleoside analogues
US5321030A (en)	1994-06-14	Creatine analogs having antiviral activity
EP0205826A2 (fr)	1986-12-30	Phosphonylméthoxyalkyl-adénines pour le traitement de maladies à virus
JP2866688B2 (ja)	1999-03-08	プリン誘導体を含有する抗ウィルス剤
HK213296A (en)	1996-12-06	9-(phosphonylmethoxyalkyl) adenines, method for their preparation and their use
JP5584865B2 (ja)	2014-09-10	抗ウイルス薬のための前駆体分子としての新規なヌクレオチド類似体
EP0138656B1 (fr)	1989-09-27	Pyrophosphates cycliques de nucléosides acycliques de la purine et de la pyrimidine, leur préparation et leur utilisation dans des compositions antivirales
US6197775B1 (en)	2001-03-06	Phosphonate nucleotide derivatives
Chalupová et al.	2005	Synthesis of N 4-Substituted Derivatives of 1-[2-(Phosphonomethoxy) ethyl] cytosine and Its Diisopropyl Ester as a Model Reaction for the Synthesis of N 4-Substituted Derivatives of Cidofovir
Gu et al.	2003	Synthesis and antiviral activity of a series of new cyclohexenyl nucleosides
JP3561272B6 (ja)	2004-12-22	抗レトロウィルス性エナンチオマー性ヌクレオチドアナログ
HK1011998B (en)	2000-10-05	Antiretroviral enantiomeric nucleotide analogs
CS248005B2 (cs)	1987-01-15	Způsob výroby derivátů 9-hydroxyethoxymethylguaninu